Lansoprazole and amoxycillin: Observations on the treatment of Helicobacter pylori infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 2, 1997, Pages 93-99

  Hazell, Stuart L ^a   Daskalopoulous, George ^b   Mitchell, Hazel M ^a   Massey, Dan ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Inner West Endoscopy Centre   (Australia)

^c Cyanamid Clinical Data Centre   (United Kingdom)

Author keywords

Amoxycillin; Helicobacter pylori; Lansoprazole; Non ulcer dyspepsia; Peptic ulcer; Treatment

Indexed keywords

AMOXICILLIN; LANSOPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BIOPSY; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031015870     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00390.x     Document Type: Article

References (43)

1. Borsch G, Mai U, Opferkuch W. Oral triple therapy may effectively eradicate Campylobcter pylori in man: A pilot study. Gastroenterology 1988; 94: A44.
2. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
3. Borody TJ, Cole P, Noonan S et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med. J. Aust. 1989; 151: 431-5.
4. Bell GD, Powell K, Burridge SM et al. Experience with triple anti-Helicobacter pylori eradication therapy: Side effects and the importance of testing the pretreatment bacterial isolate for metronidazole resistance. Aliment. Pharmacol. Ther. 1992; 6: 427-35.
5. DeCross AJ, Marshall BJ, McCallum RW, Hoffman SR, Barrett LJ, Guerrant RL. Metronidazole susceptibility testing for Helicobacter pylori-comparison of disk, broth, and agar dilution methods and their clinical relevance. J. Clin. Microbiol. 1993; 31: 1971-4.
6. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand. J. Gastroenterol. 1993; 28 (Suppl. 196): 34-7.
7. Coelho LG, Passos MC, Chausson Y, Castro LP. Five-day bismuth-free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse. Am. J. Gastroenterol. 1991; 86: 971-5.
8. Hudson N, Brydon WG, Eastwood MA, Ferguson A, Palmer KR. Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen. Aliment. Pharmacol. Ther. 1995; 9: 47-50.
9. Frotz H, Ahrends H, Hebbeln H et al. Ranitidine and clarithromycin eradicating Helicobacter pylori in patients with ulcus duodeni. Drug Res. 1995; 45: 184-6.
10. Deboer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817-20.
11. Axon ATR. The role of omeprazole and antibiotic combinations in the eradication of Helicobacter pylori: An update. Scand. J. Gastroenterol. 1994; 29 (Suppl. 205): 31-7.
12. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand. J. Gastroenterol. 1994; 29 (Suppl. 201): 16-23.
13. Iwahi T, Satoh H, Nakao M et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob. Agents Chemother. 1991; 35: 490-6.
14. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404-30.
15. Barradell LB, Faulds D, McTavish D. Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225-50.
16. Verdu EF, Fraser R, Armstrong D, Blum AL. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand. J. Gastroenterol. 1994; 29: 1065-9.
17. Price AB. The Sydney System: Histological division. J. Gastroenterol. Hepatol. 1991; 6: 209-22.
18. Mitchell HM, Lee A, Berkowicz J, Borody T. Use of serology to diagnose active Campylobacter pylori infection. Med. J. Aust. 1988; 149: 604-9.
19. Hazell SL, Borody TJ, Gal A, Lee A. Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis. Am. J. Gastroenterol. 1987; 82: 292-6.
20. Hu PJ, Li YY, Mitchell HM et al. Oxyntic and antral gastritis in the People's Republic of China: Diagnosis and relationship to Helicobacter pylori. Am. J. Gastroenterol. 1992; 87: 741-5.
21. Hazell SL. Cultural techniques for the growth and isolation of Helicobacter pylori. In: Goodwin CS, Worsley BW, eds. Helicobacter pylori. Biology and Clinical Practice. Boca Raton, Florida: CRC Press, 1993; 273-83.
22. Nakao M, Tada M, Tsuchimori, Uekata M. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. Eur. J. Clin. Microb. Infect. Dis. 1995; 14: 391-9.
23. Glupczynski Y, Burette A, Nyst JF, De PC, De KE, Deltenre M. Campylobacter pylori-associated gastritis: Attempts to eradicate the bacteria by various antibiotics and anti-ulcer regimens. Acta Gastroenterol. Belg. 1989; 51: 329-37.
24. Axon AT. Campylobacter pylori: Therapy review. Scand. J. Gastroenterol. 1989; 24 (Suppl. 160): 35-8.
25. Rune SJ, Justesen T, Hansen JM et al. Prevention of duodenal ulcer recurrence with penicillin: A double-blind, placebo-controlled trial. Scand. J. Gastroenterol. 1993; 28: 438-42.
26. Bell GD, Powell KU, Burridge SM et al. Short term: Omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori. Aliment. Pharmacol. Ther. 1992; 6: 751-8.
27. Labenz J, Gyenes E, Ruhl GH, Borsch G. Amoxycillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: A prospective, randomized, and controlled study. Gut 1993; 34: 1167-70.
28. Labenz J, Ruhl GH, Bertrams J, Borsch G. Medium-and high-dose omeprazole plus amoxycillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig. Dis. Sci. 1994; 39: 1483-7.
29. Bayerdorffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand. J. Gastroenterol. 1993; 28 (Suppl. 196): 19-25.
30. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on Helicobacter pylori and duodenal ulcer disease. Scand. J. Gastroenterol. 1993; 28 (Suppl. 196): 17-18.
31. Miehlke S, Mannes GA, Lehn N, Bayerdörffer E, Hele C, Stolte M. An increasing dose of omeprazole combined with amoxicillin improves the cure of Helicobacter pylori infection. Gastroenterology 1995; 108: A167.
32. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxycillin for cure of Helicobacter pylori infection. Scand. J. Gastroenterol. 1994; 29: 1070-5.
33. Lambert JR, Taupin D, Yeomans N et al. A randomized controlled study on the effect of omeprazole with amoxycillin in Helicobacter pylori eradication. J. Gastroenterol. Hepatol. 1994; 9: A96.
34. Koelz HR, Beglinger C, Inauen W, Blum AL, Helico-Swiss-Study Group. Double-blind comparison of three different amoxicllin (AMO) plus omeprazole (OME) regimens for eradication of Helicobacter pylori (HP) in patients with peptic ulcer. Gastroenterology 1995; 108: A133.
35. Kuipers EJ, Klinkenbergknol EC, Festen HPM et al. Long-term omeprazole therapy does not affect Helicobacter pylori status in most patients. Scand. J. Gastroenterol. 1993; 28: 978-80.
36. Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-16.
37. Danon SJ, O'Rourke JL, Moss ND, Lee A. The importance of local acid production in the distribution of Helicobacter felis in the mouse stomach. Gastroenterology 1995; 108: 1386-95.
38. Nilius M, Manheller I, Eckelmann S, Sauerbruch T, Malfertheiner P. Proton pump inhibitor (PPI) pretreatment affects Helicobacter pylori sensitivity to antibiotics. Gut 1995; 37 (Suppl. 1): A18.
39. Belli WA, Fryklund J. Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells. Antimicrob. Agents Chemother. 1995; 39: 1717-20.
40. McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 1994; 107: 738-43.
41. Mendz GL, Burns BP, Hazell SL. Characterization of glucose transport in Helicobacter pylori. Biochim. Biophys. Acta 1995; 1244: 269-76.
42. Hazell SL, Hennessy WB, Borody TJ et al. Campylobacter pyloridis gastritis II: Distribution of bacteria and associated inflammation in the gastroduodenal environment. Am. J. Gastroenterol. 1987; 82: 297-301.
43. Kuipers EJ, Uyterlinde, Pena S et al. Increase of Helicobacter pylori corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am. J. Gastroenterol. 1995; 90: 1401-6.